Table 3.
Association of VFA results with new prescription for fracture prevention medication (HC-1, HC-2 and HC-3)
| Predictor | Odds ratio (95 % C.I.) |
|---|---|
| VFA positive for vertebral fracture | 3.5 (2.0–6.2) |
| Age: <65 (ref.) | 1.0 |
| 65–69 | 1.4 (0.7–2.7) |
| 70–74 | 1.1 (0.6–2.2) |
| 75–79 | 0.9 (0.4–1.8) |
| 80 or older | 1.5 (0.8–3.0) |
| Sex (male vs. female) | 1.5 (0.9–2.5) |
| Prior fracture | 0.8 (0.5–1.3) |
| Current glucocorticoid | 1.7 (1.0–2.8) |
| Femoral neck BMD T-score (per increase of 1.0) | 0.56 (0.37–0.84) |
| Study sitea | HC-2: reference |
| HC-1: 1.9 (1.3–2.8) | |
| HC-3: 0.4 (0.2–0.7) | |
| Study site—VFA results interaction | HC-2: reference |
| HC-1: 0.66 (0.3–1.6) | |
| HC-3: 1.5 (0.5–5.0) |
n =945; data missing on one or more covariates for 132 individuals
a
The reasons for the differences for fracture prevention medication among osteopenic individuals between the three sites is unclear; since these odds ratios are adjusted for results of the VFA, it is possible that these odds reflect a higher likelihood of using medication to prevent bone loss among osteopenic individuals at HC-1, but a further manual medical record review study would be required to investigate this